AgomAb Therapeutics AGMB 深 沪
等待开盘 08-27 09:30:00 美东时间
14.28
+0.260
+1.85%
华盛通- 最 高14.60
- 今 开14.19
- 成交量 24.36万股
- 最 低 13.58
- 昨 收 14.02
- 总市值 7.03亿
- 52周最高 17.82
- 市盈率 静 --
- 换手率 0.49%
- 52周最低 8.75
- 委 比 97.71%
- 总股本 4924.80万
- 历史最高 17.82
- 量 比 2.22
- 振 幅 7.28%
- 历史最低 8.75
- 每 手 1
- 风险率 1.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞杰金融维持英伟达"强力买入"评级，目标价从330美元升至352美元；瑞穗下调美光科技目标价从1375美元降至1300美元
今日重点评级关注：摩根大通：维持Ultragenyx Pharmaceutical"超配"评级，目标价从75美元升至80美元；瑞杰金融：维持英伟达"强力买入"评级，目标价从330美元升至352美元
08-26 08:37
Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating.
08-19 18:35
AgomAb Therapeutics NV reports 1H results
AgomAb Therapeutics NV press release (AGMB): 1H Cash, cash equivalents and short-term cash investments totaled €252.0 million as of June 30, 2026. Net loss was €31.0 million for the six months ended ...
08-07 22:16
AgomAb Therapeutics H1 EPS $(0.93)
AgomAb Therapeutics (NASDAQ:AGMB) reported quarterly losses of $(0.93) per share.
08-07 05:52
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34
B. Riley Securities analyst William Woods initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Buy rating and announces Price Target of $34.
07-23 22:13
美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
HC Wainwright & Co. Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $35
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Buy rating and announces Price Target of $35.
06-22 19:01
Agomab Secures US Patent For AGMB-447, Investigational Inhaled Lung-Restricted Small Molecule Inhibitor Of ALK5 For Idiopathic Pulmonary Fibrosis Treatment
Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No.
03-26 19:11
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
